| 000 | 01666 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516064836.0 | ||
| 264 | 0 | _c20120626 | |
| 008 | 201206s 0 0 eng d | ||
| 022 | _a1573-7241 | ||
| 024 | 7 |
_a10.1007/s10557-011-6358-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNicholls, Stephen J | |
| 245 | 0 | 0 |
_aInhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. _h[electronic resource] |
| 260 |
_bCardiovascular drugs and therapy _cFeb 2012 |
||
| 300 |
_a71-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAcetates _xtherapeutic use |
| 650 | 0 | 4 |
_aAcute Coronary Syndrome _xdrug therapy |
| 650 | 0 | 4 | _aAtorvastatin |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aHeptanoic Acids _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aIndoles _xtherapeutic use |
| 650 | 0 | 4 |
_aInflammation _xdrug therapy |
| 650 | 0 | 4 | _aKeto Acids |
| 650 | 0 | 4 |
_aPhospholipases A2, Secretory _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrroles _xtherapeutic use |
| 700 | 1 | _aCavender, Matthew A | |
| 700 | 1 | _aKastelein, John J P | |
| 700 | 1 | _aSchwartz, Gregory | |
| 700 | 1 | _aWaters, David D | |
| 700 | 1 | _aRosenson, Robert S | |
| 700 | 1 | _aBash, Dianna | |
| 700 | 1 | _aHislop, Colin | |
| 773 | 0 |
_tCardiovascular drugs and therapy _gvol. 26 _gno. 1 _gp. 71-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10557-011-6358-9 _zAvailable from publisher's website |
| 999 |
_c21335962 _d21335962 |
||